Eliminating assembled neurofilaments (NFs) from axons or misaccumulating NFs in motor neuron cell bodies strongly slows disease in mouse models of mutant superoxide dismutase 1 (SOD1)-induced amyotrophic lateral sclerosis. One proposal for how reducing axonal NFs can increase survival is that the multiphosphorylated tail domains of the two larger NF subunits act in motor neuron cell bodies as phosphorylation sinks where they mitigate cyclin-dependent kinase 5 dysregulation induced by mutant SOD1. Elimination by gene targeting in mice of the NF medium and NF heavy tail domains and their 58 known phosphorylation sites accelerates aberrant phosphorylation of other neuronal substrates while leaving overall NF content unaltered. However, disease onset is significantly delayed and survival is extended, inconsistent with the ameliorative property of altered NF content protecting by serving as substrates for dysregulation of any NF kinase. Moreover, at comparable disease stages significantly more surviving motor neurons and axons were found in SOD1 mutant mice deleted in the NF tails than in similar mice with wild-type NFs. This finding supports noncell autonomous toxicity in SOD1 mutant-mediated amyotrophic lateral sclerosis: removal of the NF tails slows damage developed directly within motor neurons, but SOD1 mutant damage within nonneuronal supporting cells reduces motor neuron functionality.
A myotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease that is responsible for Ϸ1 in 1,000 deaths (1) . Dominant missense mutations in the gene for the cytoplasmic Cu͞Zn superoxide dismutase 1 (SOD1) are responsible for Ϸ20% of familial ALS cases (2) . Despite the ubiquitous expression of SOD1 (3), mutations in this protein produce a disease that selectively kills upper and lower motor neurons (reviewed in ref. 4) . Mice overexpressing mutant SOD1 develop late-onset, ALS-like disease comparable to human ALS (5-7), whereas mice deleted in SOD1 do not (8) . This finding has led to the conclusion that mutant SOD1-mediated ALS is caused by an acquired toxicity unrelated to dismutase activity (7, 9) . Aberrant oxidative chemistry, mutant aggregation especially onto spinal mitochondria (10) , and glutamate excitotoxicity (7, 11) are among the possible hypotheses that have been formulated to explain the toxic property of mutant SOD1 (4) . Furthermore, although it is mainly the large motor neurons that die in ALS, mutant SOD1-mediated toxicity is noncell-autonomous, requiring mutant expression within multiple spinal cord cell types (12) .
One of the longest-standing hypotheses for a mechanistic contributor to ALS is involvement of abnormal neurofilament (NF) organization. Indeed, aberrant accumulations of NFs are a common pathological hallmark in both sporadic and familial ALS (13) (14) (15) as well as in some mutant SOD1 mouse models (5, 16, 17) . NFs are obligate heteropolymers of NF light (NF-L), NF medium (NF-M), and NF heavy (NF-H) subunits (18, 19) and are the most abundant structural components of large myelinated axons, the neurons most at risk in human ALS (20) and mutant SOD1 mouse models (7) . The large tail domains of NF-M and NF-H are nearly stochiometrically phosphorylated and are responsible for assembly of a 3D, crosslinked axoplasm that supports acquisition of normal axonal caliber (21) . Interestingly, accumulation of modest levels of a point mutation in NF-L also produces an ALS-like motor neuron disease in mice (22) .
Several prior efforts have altered NF composition in SOD1 mutant mice, including deletion of NF-L in SOD1 G85R (23) or SOD1 G37R mice (24) and NF-H overexpression in SOD1 G37R (25) or SOD1 G93A mice (26) . Disruption of the NF-L gene removed all axonal NFs, with unassembled NF-M and NF-H subunits accumulated in the neuronal perikaryon. This genetic alteration delayed disease onset and extended survival in SOD1 G85R mice by Ϸ1.5 months, despite the significant disadvantage of loss of Ϸ15% of motor neurons early in postnatal life in the absence of NFs (23) . On the other hand, increased expression of NF-H decreased axonal NF content by trapping most in the motor neuron cell bodies, extending life span in SOD1 G37R mice by 3-6.5 months, by far one of the most striking slowings of SOD1-mediated disease to date in mice (24, 25) .
Two models have been proposed to explain how altering axonal NFs can alleviate mutant SOD1 toxicity (outlined in Fig.  5 , which is published as supporting information on the PNAS web site). In the first, a beneficial effect within the cell bodies has been postulated from the increased perikaryal content of NF-M and NF-H (filamentous or as subunits), whose multiphosphorylation sites in their tail domains could serve as phosphorylation sinks for buffering mutant SOD1-induced hyperactive cyclindependent kinase 5 (Cdk5) (24, 25) . This first model is based on the finding that slowing of disease after overexpression of NF-H reduced hyperphosphorylation of tau, one of the target proteins of misregulated Cdk5 (24) . Although deletion of the neuronal Cdk5 activator p35 does not alter the disease course in mutant SOD1 mice (27) , increased phosphorylation of tau (and probably other substrates) during disease progression may arise from sustained action of alternative Cdk5 activators, such as p39 (28) , or other mutant SOD1-induced kinases.
An alternative hypothesis (23, 29) has proposed that the protective effect of altering NF content is primarily an axonal one, in which a reduced burden of NFs, especially the interactions mediated by their phosphorylated tail domains, reduces the NF-dependent slowing of slow axonal transport, which has been shown to directly depend on the phosphorylation state of NF-tail domains (30) . Because there is a presymptomatic deficit in transit of cargoes of slow axonal transport in mutant SOD1 mice (29) , this latter hypothesis predicts that removing NF-M and NF-H tail domains (and all of their known phosphorylation sites) will reduce axonal crosslinking and restore more normal transport.
These two models make very different predictions of what would happen to SOD1-mediated toxicity in mice with normal NF content but missing the NF-M and NF-H tail domains and their phosphorylation sites. If the first hypothesis is correct, disease would be accelerated (or unchanged), whereas the axonal hypothesis predicts slowed mutant SOD1-mediated disease. We have now tested these models by generating and analyzing disease in SOD1 G37R mice in which gene replacement was used to remove the tail domains of NF-M, NF-H, or both. (Fig. 1 A) were generated by this last method. Average disease onset and end stage were indistinguishable between animals derived from either breeding approach, mitigating concerns regarding possible inf luences of the mixed genetic backgrounds (data not shown). More than 600 mice were generated, and the number of progeny obtained for each genotype was as expected for Mendelian transmission. Genotyping was performed as described (21, 29) . Mice were weighed weekly as an objective measure of disease course. End stage was defined by the inability of an animal to right itself within 20 s when placed on its side. SDS͞PAGE and Immunoblotting. Sciatic nerve and spinal cord protein extracts (both at hind limb weakness) were made and analyzed as described (33) . Protein extracts (15 g) from one to three animals per genotype were separated individually by SDS͞PAGE using gels containing 7.5% (NFs and tau) or 12.5% (SOD1) polyacrylamide and transferred to nitrocellulose (34) . The NF-L subunit was identified by using an affinity-purified rabbit polyclonal antibody (1͞400) (35) , whereas human and mouse SOD1 were detected with a rabbit polyclonal antibody (1͞1,500) (3). Total tau was detected by a phosphorylation-independent mouse mAb (BioSource International, Camarillo, CA; Tau-5; 1͞1,000), whereas phosphotau was detected by a mouse mAb recognizing an epitope containing the phosphorylated Ser-409 (PG5, a kind gift of Peter Davies, Albert Einstein College of Medicine, Bronx, NY; 1͞100). Membranes were incubated with the antibodies as described (21) .
Materials and Methods
Quantitation of Axons, Neurons, and Neuromuscular Junctions. For tissue collection mice were perfused with 4% formaldehyde. Both L5 motor roots from each animal were counted and averaged (21) , and axonal caliber distributions were determined as described (21) . Spinal cords and gastrocgnemius muscles were cryoprotected and snap-frozen in isopropanol in TissueTek (Sakura, Torrance, CA). Thirty-micrometer serial spinal cord cryosections were cut between sacral S1 and lumbar L2, and every sixth section was stained with cresylviolet-acetate (Sigma). A total of 20 lumbar L3-L6 sections per animal were analyzed, and both the total and the large (Ͼ25 m in diameter) ventral horn motor neurons were counted. One gastrocnemius muscle per animal was analyzed, 40-m serial cryosections were cut, and every 12th section was collected. A total of eight sections per animal were analyzed. Floating sections were blocked with 1.5% bovine albumin in PBS and 0.5% Tween 20 and stained with polyclonal rabbit antibodies against synaptophysin (1͞50) (Zymed) and NF-L (1͞50) (35) in PBS and 0.3% Triton X-100 for 4 days at 4°C. ␣-Bungarotoxin coupled to Alexa Fluor 488 (1͞250) (Molecular Probes) was added, and antibodies were detected by goat anti-rabbit Cy3-coupled secondary antibodies (1͞250) (Jackson ImmunoResearch). End-plate analysis was done on a Olympus confocal microscope using FV1000. . Control animals were 6 months old, whereas mutant SOD1 mice were at hind limb weakness. Equal loading is shown by Coomassie and the endogenous mouse SOD1 (mSOD1), whereas total tau was detected with tau-5 and phospho-tau with PG5 antibodies. Note that because overall total tau levels are down-regulated in mutant SOD1 mice (see text) the ratio of phosho͞unphospho-tau is actually higher in the NF-(M͞H) wild-type ͞SOD1 G37R mice than in the control NF-(M͞H) tail⌬ mice, although the total phospho-tau level is reduced, consistent with a mutant SOD1-induced deregulation of Cdk5 (24) .
Results

Removal of the NF-M͞H Tail Domains Delays Disease Onset and
Prolongs the Survival of Mutant SOD1 Mice. NF-(M͞H) tail⌬ mice have been described in which gene replacement was used to eliminate the tail domains of both NF-M and NF-H (21). These were mated to a mutant SOD1 mouse (SOD1 G37R ; line 106) that reaches disease end stage by 11.8 months (Ϯ0.2 SEM, n ϭ 12). Levels of mutant accumulation as well as timing of disease onset and survival were almost identical to the SOD1 G37R mouse (line 29), which was used in two prior experiments in which deletion of NF-L (24) G37R ] with all relevant genotypes in a common set of littermates (Fig. 1 A) . We have previously shown that deletion of the NF tail domains did not change the levels of the accumulated NF protein subunits (21) . Using quantitative immunoblotting for NF-L, the major subunit of assembled NF heteropolymers, we confirmed the unchanged NF levels in sciatic nerve extracts from mutant SOD1 mice with or without the NF-M and͞or NF-H tail domains (Fig. 1B) . Importantly, removal of the NF tail domains did not affect mutant SOD1 protein levels (Fig. 1B) .
Disease onset and progression were documented with multiple measures, including hind limb weakness, leg spread when suspended by the tail, gait abnormalities, and weight loss, the last of which provided a simple, rapid, and objective measure (36, 37) . No mice without mutant SOD1 [e.g., NF-(M͞H) wild-type or NF-(M͞H)
tail⌬ mice] developed any hind limb symptoms or weight loss by 14 months of age, the oldest age analyzed (n ϭ 10 each; data not shown). Four disease stages were defined: presymptomatic (before onset, at 6 months), onset (at the weight peak), hind limb weakness (at 10% weight loss, which was invariably accompanied by alterations in gait, development of tremors, and failure of hind limb splaying when suspended by the tail), and end stage (hind limb paralysis).
In a direct test of the phosphorylation sink hypothesis for NF tail domains in mutant SOD1 mice (24) (Fig. 5) wild-type ͞SOD1 G37R mice (Fig. 1C) . Indeed, phosphotau (Ser-409) was increased in mice lacking NF tail domains, independent of the presence of mutant SOD1. This effect was true despite an overall down-regulation of total tau in symptomatic SOD1 mutant animals, perhaps reflecting loss of motor neurons. Thus, NF tail domains can and do serve as phosphorylation sinks whose loss is accompanied by increased phosphorylation by NF kinases (including Cdk5) of other neuronal components.
If the increased perikaryal accumulation of NFs (and hence increased buffering for dysregulated kinases) underlies their ability to ameliorate disease, then removing the NF tail domains should increase detrimental hyperphosphorylation of deregulated kinase targets like tau and accelerate mutant SOD1-mediated disease (Fig. 5) . Just the opposite was found: NF-(M͞H) wild-type ͞SOD1 G37R mice reached onset at 7.1 months (Ϯ0.2, n ϭ 17) before significant loss of motor axons (38) and correlating well with slowing of axonal transport at 6-7 months, the earliest change in these mice that express relatively low levels of SOD1 G37R (29) . Hind limb weakness was reached at 10.1 months (Ϯ0.2, n ϭ 17), whereas end stage occurred at 11.8 months (Ϯ0.2, n ϭ 12).
In contrast, NF-(M͞H) tail⌬ ͞SOD1 G37R mice did not reach onset until 9.1 months (Ϯ0.4, n ϭ 15) ( Fig. 2A) , representing a 2-month delay in disease onset. Likewise, in NF-(M͞H) tail⌬ ͞SOD1 G37R mice hind limb weakness was delayed 2.5 months, occurring at 12.6 months (Ϯ0.3, n ϭ 15), a time when most of the NF-(M͞H) wild-type ͞SOD1 G37R mice had already died (Fig. 2B ). NF-(M͞H) tail⌬ ͞SOD1 G37R mice reached end stage at 13.9 months (Ϯ0.3, n ϭ 10), 2.1 months later than NF-(M͞H) wild-type ͞SOD1 G37R mice (Fig. 2C) . All three delays reached high statistical significance (using ANOVA and Bonferroni͞Dunn post hoc test: P Ͻ 0.0002). Delay from loss of the tail domains was additive: mice deleted in only one of the two NF tail domains showed smaller, but still significant, delays in all three measured disease stages (Fig. 2) .
Motor Neurons Lacking the NF-M͞H Tail Domains Are Protected
Against Mutant SOD1 Toxicity. To determine whether at similar disease stages the extent of neurodegeneration was the same in animals with or without NF tail domains, lumbar (L5) motor (ventral) roots were examined and all axons within them were counted. Despite decreased axonal calibers in NF-(M͞H) tail⌬ mice relative to mice with wild-type NFs (as reported earlier) (21), both at hind limb weakness and end stage, there were significantly more surviving axons in the NF-(M͞H) tail⌬ ͞ SOD1 G37R mice relative to those in the NF-(M͞H) wild-type ͞ SOD1 G37R animals ( Fig. 3 A-F) . This difference was statistically significant (using ANOVA and Fisher's probable least-squares difference post hoc test: P Ͻ 0.0065) and resulted at hind limb weakness in 40% and at end stage in 64% more surviving axons for NF-(M͞H) tail⌬ ͞SOD1 G37R mice than for NF-(M͞H) wild-type ͞ SOD1 G37R animals (Fig. 3G) . The absolute number of remaining L5 motor axons found in NF-(M͞H) tail⌬ ͞SOD1 G37R mice at hind limb weakness was 72% (724 Ϯ 26 axons; n ϭ 3) of 14-month-old control NF-(M͞H) wild-type animals (1,008 Ϯ 61 axons; n ϭ 3). In contrast, at the same disease stage, NF-(M͞H)
wild-type ͞ SOD1 G37R mice had only 51% (517 Ϯ 29 axons; n ϭ 4) surviving axons. Similarly, by end stage NF-(M͞H) tail⌬ ͞SOD1 G37R mice had 61% (613 Ϯ 51 axons; n ϭ 3) of the normal number of axons, whereas NF-(M͞H)
wild-type ͞SOD1 G37R mice had many fewer, only 37% (374 Ϯ 29 axons; n ϭ 4) (Fig. 3G and Table 1 , which is published as supporting information on the PNAS web site).
Even more surprisingly, end-stage NF-(M͞H) tail⌬ ͞SOD1
G37R
mice not only showed more surviving axons than did endstage NF-(M͞H) wild-type ͞SOD1 G37R mice, they retained more than NF-(M͞H) wild-type ͞SOD1 G37R mice at the earlier hind limb weakness stage (Fig. 3G) . This outcome was true despite a slight reduction in axonal numbers (15% less; P ϭ 0.0457) in NF-(M͞H) tail⌬ mice and presymptomatic NF-(M͞H) tail⌬ ͞SOD1 G37R mice relative to the NF wild-type animals both in the presence (presymptomatic) and absence of SOD1 G37R (Fig. 3G and Table 1 ). Because interpretation of axonal numbers in motor roots could be confounded by potential proximal sprouting, L3-L6 ventral horn motor neurons were also counted. Consistent with the axon numbers, there were more surviving motor neurons at similar disease stages in the NF-(M͞H) tail⌬ ͞SOD1 G37R mice as compared with the NF-(M͞H) wild-type ͞SOD1 G37R mice [77% and 61% at hind limb weakness and end stage, respectively, whereas only 62% and 37% remained in NF-(M͞H) wild-type ͞SOD1 G37R mice; Fig. 3H G37R mice had more axons and surviving motor neurons than NF-(M͞H) wild-type ͞SOD1 G37R mice, we assessed two additional parameters to more directly test the functionality of these remaining motor neurons: retention of axonal caliber and the integrity of surviving neuromuscular junctions. In presymptomatic mice before onset, the axon caliber distribution in both the NF-(M͞H) wild-type ͞SOD1 G37R and the NF-(M͞H) tail⌬ ͞SOD1 G37R mice were as in their respective control animals without mutant SOD1 (Fig. 4A) . At hind limb weakness NF-(M͞H) wild-type ͞SOD1 G37R mice retained 51% of their L5 ventral root axons (Fig. 3G) , with essentially all of the loss arising from the pool of larger caliber axons (Fig. 4A) . In contrast, at the same disease stage, NF-(M͞H) tail⌬ ͞SOD1 G37R mice still had 72% of their axons remaining (Fig. 3G) and a bimodal caliber distribution essentially the same as in the control NF-(M͞H) tail⌬ animals (Fig.  4A) . Finally, at end stage with still 61% remaining axons in the NF-(M͞H) tail⌬ ͞SOD1 G37R mice this bimodal distribution was reduced but still partly present, with the main loss in the large-caliber axons (Fig. 4A) . Thus, although the axonal degeneration is slowed in NF-(M͞H) tail⌬ ͞SOD1 G37R mice, in both NF-(M͞H) wild-type and NF-(M͞H) tail⌬ mice SOD1 mutant toxicity produced losses only of the larger-caliber axons even at end stage.
The percentage of innervation remaining was determined at the end plates of neuromuscular junctions of the gastrocnemius, one of the affected hind limb muscles and innervated by L3-L5 spinal nerves. This process revealed robust denervation at the hind limb weakness stage in the NF-(M͞H) wild-type ͞SOD1 G37R mice, with only 25% remaining innervated end plates (Fig. 4B) . However, at the same disease stage, more than twice as many (60%) of all analyzed end plates were still innervated in the 
NF-(M͞H)
tail⌬ ͞SOD1 G37R mice, a difference that was highly significant (using ANOVA and Fisher's probable least-squares difference post hoc test: P ϭ 0.0082) (Fig. 4B and 
Discussion
We have shown that the removal of the large phosphorylated tail domains of NF-M and NF-H delays disease onset and extends survival of mutant SOD1 mice by 2 months, coupled to a partial protection of the entire motor neuron unit (cell body, axon, and end plate). The ameliorative effects on onset and survival are similar in magnitude to those produced by eliminating axonal NF assembly altogether (by deletion of the NF-L gene) (23) . Further, we showed that NF tail domains can act as phosphorylation sinks that minimize phosphorylation by Cdk5 or other NF kinases. Nevertheless, removal of these phosphorylation sites led to a delay of disease rather than the acceleration predicted by a kinase dysregulation model. Clearly, the multiphosphorylation sites on both NF-M and NF-H, and hence the possibility that they could act as phosphorylation sinks to mitigate dysregulated Cdk5 (or any other NF kinase), are not an essential mechanistic contributor to diminished toxicity of ALS-causing SOD1 mutants in mice of altered NF subunit composition.
What then can explain the beneficial effect of removing NFs from the axons? Removal of the large, multiply phosphorylated NF tail domains produces smooth, wavy NFs lacking most of the numerous cross bridges between adjacent NFs and microtubules (21) . Furthermore, the reduction of axonal NF content and the removal of the NF-H tail domain has been shown to accelerate the net rate of movement of cargoes in slow axonal transport (31, (39) (40) (41) . Site-directed mutation to produce nonphosphorylatable NFs or mimic constitutive phosphorylation in primary neurons has been shown to accelerate or retard transport, respectively (30) . On the other hand, SOD1 mutants have been shown to inhibit movement of slow axonal transport cargoes beginning at presymptomatic disease stages (29) . Mutant SOD1 action may also inhibit retrograde transport, as indicated by a striking distal accumulation of mitochondria and synaptic vesicles at the presynaptic terminals of motor neurons (42) . Collectively, these data identify establishment of a more flexible axoplasm that can enhance anterograde transport as one mechanism underlying the benefit of removing the NF-M and NF-H tail domains in SOD1 mutant-mediated motor neuron disease.
The robust benefit in slowing SOD1 mutant-mediated disease in NF-(M͞H) tail⌬ ͞SOD1 G37R mice was found to a lesser degree in mice lacking either one of the NF tail domains (NF-M tail⌬ ͞ SOD1 G37R and NF-H tail⌬ ͞SOD1 G37R mice), indicating an additive effect of deleting both NF tail domains. However, and quite surprisingly, there was an additional neuroprotection resulting in many more surviving motor neuron units at a similar disease stage as compared with the initial mutant SOD1 mice with normal NF content. This motor neuron sparing, both in axon number and caliber distribution, required deletion of both NF-M and NF-H tail domains (Table 1 and data not shown).
These findings raise a perplexing question in the mechanism of SOD1 mutant-mediated disease: how can a similar clinical deficit, such as hind limb weakness or hind limb paralysis be generated despite different numbers of surviving motor neuron units? Removal of the NF tail domains protects motor neurons against mutant SOD1 toxicity, slows disease, and preserves more neurons even as paralysis ensues. It also slows axonal degeneration, including synaptic retraction, an event proposed to be one of the earliest in mutant SOD1-mediated ALS in mice (43) , even though function is not preserved. Thus, removal of the NF tail domains reveals that mutant SOD1 motor neurons lose functionality before obvious signs of denervation and axonal degeneration. Interestingly, a similar phenomenon was recently reported in mutant SOD1 mice that were treated with a virus to produce RNA interference to lower synthesis and accumulation of mutant SOD1. Viral injection into muscles and subsequent retrograde transport to the motor neuron cell bodies yielded mice that survived much longer than untreated controls, but just as we have found here, when these animals ultimately reach end stage they retained an increased number of surviving motor neurons when compared with control animals (44) .
In this respect it is of interest that analysis of chimeric mice that are a mixture of wild-type and SOD1 mutant-expressing cells have been used to demonstrate that toxicity is noncell autonomous (12) , with mutant action within nonneuronal cells required for neuronal loss. Disease stage may thus be determined by the collective damage from mutant SOD1 action within multiple cell types, especially those neighboring the motor neurons, including astrocytes, microglia, Schwann cells, and the muscle cells to which they attach. For NFs, the simplest view is that because NF-M and NF-H are preferentially expressed in large, myelinated motor neurons, removal of the NF tail domains has a direct influence only on those neurons, whereas damage in the nonneuronal cells progresses unabated. Thus, a local protective effect from removing the NF tail domains slows pathology within the motor neuron, whereas a strong toxic environment reduces its functionality.
